Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Liabilities: 2021-2025

Historic Total Liabilities for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to $80.8 million.

  • Abivax's Total Liabilities fell 81.75% to $80.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $80.8 million, marking a year-over-year decrease of 81.75%. This contributed to the annual value of $168.7 million for FY2024, which is 26.14% up from last year.
  • Per Abivax's latest filing, its Total Liabilities stood at $80.8 million for Q2 2025, which was down 55.75% from $182.5 million recorded in Q1 2025.
  • Abivax's 5-year Total Liabilities high stood at $442.6 million for Q2 2024, and its period low was -$172.6 million during Q1 2024.
  • Over the past 3 years, Abivax's median Total Liabilities value was $151.2 million (recorded in 2023), while the average stood at $139.3 million.
  • Examining YoY changes over the last 5 years, Abivax's Total Liabilities showed a top increase of 205.76% in 2025 and a maximum decrease of 81.75% in 2025.
  • Quarterly analysis of 5 years shows Abivax's Total Liabilities stood at $91.7 million in 2021, then dropped by 27.36% to $66.6 million in 2022, then skyrocketed by 100.77% to $133.7 million in 2023, then climbed by 26.14% to $168.7 million in 2024, then tumbled by 81.75% to $80.8 million in 2025.
  • Its Total Liabilities was $80.8 million in Q2 2025, compared to $182.5 million in Q1 2025 and $168.7 million in Q4 2024.